Late-onset Lafora disease with prominent parkinsonism due to a rare mutation in EPM2A by Lynch, DS et al.
Clinical/Scientific
Notes
David S. Lynch, MRCPI
Nicholas W. Wood, PhD
Henry Houlden, PhD
Neurol Genet
2016;2:e101; doi: 10.1212/
NXG.0000000000000101
LATE-ONSET LAFORA DISEASE WITH
PROMINENT PARKINSONISM DUE TO A RARE
MUTATION IN EPM2A
Lafora disease (LD) is an autosomal recessive form of
progressive myoclonic epilepsy that is caused by mu-
tations in EPM2A, encoding laforin, and NHLRC1
(EPM2B), encoding malin.1 LD is classically
described with onset in early teenage years. Patients
develop myoclonus, epilepsy, visual hallucinations,
and psychosis. Dementia is a prominent feature and
often occurs in the late teenage years. LD typically
progresses quickly, and patients become bedridden
and dependent within 10 years of symptom onset,
with life expectancy in the early 20s.2,3 Only a small
number of late-onset cases of LD have been
described. Even then, these so-called late-onset cases
have typically presented in the 20s, with dementia
occurring in the early 30s. We describe a patient with
extremely late onset and extended survival with prom-
inent parkinsonism due to a novel EPM2A variant.
The patient was a 53-year-old woman of South
Asian ancestry who presented to the neurology
clinic with a slowly progressive history of bradyki-
nesia, upper and lower limb spasticity, and cogni-
tive decline.
The patient had reached developmental mile-
stones at appropriate ages and was cognitively nor-
mal as a young adult, graduating from university.
Her parents were first cousins. She had a history
of jerks affecting the upper and lower limbs, which
had been present since her teenage years and were
not troublesome. In her early 20s, she experienced
several generalized seizures and was diagnosed with
myoclonic epilepsy. The jerks and seizures ceased
with sodium valproate treatment, and she eventu-
ally discontinued it.
The patient’s sister was similarly affected with
myoclonic jerks and seizures; later she developed
memory and mobility difficulties. Her father had
late-onset Parkinson disease.
When the patient’s seizures recurred at age 43,
sodium valproate was recommenced. On examina-
tion at age 45, she was diagnosed with mild cog-
nitive impairment. The EEG taken was markedly
abnormal with frequent generalized spike-and-
wave complexes occurring every minute. Over
the following 5 years, she continued to decline
cognitively and stopped working. This was fol-
lowed by the development of an extrapyramidal
movement disorder with bradykinesia, cogwheel
rigidity in the limbs, and difficulty mobilizing.
On examination, she was found to have a dystonic
facies with truncal and limb rigidity and marked
bradykinesia. She had eyelid-opening apraxia,
tonic deviation of the eyes upward, and impaired
vertical eye movements. Self-injurious behavior
developed, causing severe dermatitis artefacta to
the nose, requiring reconstructive surgery.
A DATscan at age 53 demonstrated absent
tracer uptake in the putamen bilaterally with
severely reduced activity in the right caudate
nucleus. Brain MRI revealed mild atrophy (figure).
Skin and muscle biopsies were normal. Peripheral
and cervical somatosensory evoked potentials re-
vealed abnormally large amplitude cortical re-
sponses, suggesting cortical myoclonus.
The patient’s family reported that during sleep she
would vocalize loudly and move her limbs, raising
a suspicion of REM sleep behavioral disorder; how-
ever, overnight sleep study demonstrated catathrenia.
There was a short-lived response to levodopa (600
mg/d) and 5 mg selegiline with little response to
dopamine agonists. Over the following years, she con-
tinued to decline and became increasingly dependent.
She developed dysphagia and died at age 59 of a lower
respiratory tract infection.
Exome sequencing was carried out, and we identi-
fied candidate genes by prioritizing rare (minor allele
frequency ,0.01), homozygous, and nonsynony-
mous coding variants. This identified 38 such var-
iants, only one of which was found in a gene
previously implicated in neurologic disease, EPM2A.
We identified a likely pathogenic homozygous
mutation in EPM2A (c.962T.G p. F321C). The
variant occurs at a highly conserved residue and has
a frequency of 0.000008242 in the Exome Aggrega-
tion Consortium database.4 It was also found in the
homozygous state in the patient’s affected sister and
heterozygous state in 2 unaffected siblings.
The EPM2A gene is alternatively spliced into
at least 5 isoforms. Of the 2 major isoforms, one
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is 317 amino acids long and localizes to the
nucleus while the other is 331 amino acids long
and localizes to the rough endoplasmic reticulum.5,6
Almost all mutations in EPM2A have been found
in the region of the gene common to both major
isoforms.
The mutation found in this patient is predicted
to affect only the cytoplasmic isoform of the lafor-
in protein. This may explain the extremely late
onset and slow progression of disease in our
patient. From previous work, we can hypothesize
that in our patient the cytoplasmic isoform has
severely reduced the phosphatase activity6 while
the nuclear isoform is unaffected.
Prominent parkinsonism has not previously
been associated with LD and may have developed
in the context of our patient’s long survival. This
case broadens the phenotype of LD and provides
evidence of a genotype-phenotype correlation in
the EPM2A gene.
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Figure EPM2A gene and imaging appearance
(A) Schematic diagram of the 2 major isoforms of laforin illustrating the F321C mutation, only affecting the cytoplasmic isoform of the protein. (B, C, E, F)
MRI demonstrating only mild atrophy. The brainstem and basal ganglia are normal. (D) DATscan at age 53 shows severely reduced tracer uptake in the right
caudate nucleus. (G) DATscan at age 59 shows severely reduced tracer uptake in the basal ganglia with increased background signal, indicating a profound
dopaminergic deficit.
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